Related Experiment Video
Updated: Jun 10, 2025
04:33
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
Published on: April 26, 2024
614
Digital cognitive-behavioral therapy for insomnia in patients with multiple sclerosis: A multiple baseline
Sven Alfonsson1, Alva Olofsson Liljeholm2, Camilla Adel3
1Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm Health Care Services, Stockholm County Council, Stockholm, Sweden.
Sleep Medicine
|October 17, 2024
Summary
Video-based cognitive behavioral therapy for insomnia (VCBT-I) effectively treated insomnia in multiple sclerosis (MS) patients. This approach improved sleep, reduced depression and anxiety, and enhanced quality of life for individuals with MS and insomnia.
Area of Science:
- Neurology
- Sleep Medicine
- Psychiatry
Background:
- Insomnia affects over 20% of multiple sclerosis (MS) patients.
- Cognitive Behavioral Therapy for Insomnia (CBT-I) shows promise for MS-related sleep issues.
- Video-based CBT-I (VCBT-I) offers a remote, accessible treatment option.
Purpose of the Study:
- To assess the efficacy of VCBT-I in patients with comorbid insomnia and MS.
- To evaluate the impact of VCBT-I on sleep quality, psychological symptoms, and quality of life.
Main Methods:
- Pilot study involving ten participants with MS and insomnia.
- Utilized video-based cognitive behavioral therapy for insomnia (VCBT-I).
- Assessed outcomes using Insomnia Severity Index (ISI), PHQ-9 (depression), and GAD-7 (anxiety).
Main Results:
- Significant reductions in total wake time observed in 60% of participants.
- Clinically significant improvements in waking time for 70% of participants.
- Eight participants achieved insomnia remission based on ISI scores.
- Observed improvements in depression and anxiety symptoms.
- Participants reported enhanced quality of life and high treatment satisfaction.
Conclusions:
- VCBT-I is a well-tolerated and effective treatment for insomnia in individuals with MS.
- This modality shows potential for alleviating sleep disturbances and associated psychological symptoms.
- Further research may be needed to optimize fatigue management within VCBT-I for MS patients.
More Related Videos
Related Concept Videos
01:19Management of Insomnia
234
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
234
01:27Insomnia
79
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
79
01:15REM Sleep Behavior Disorder
158
REM Sleep Behavior Disorder (RBD) is a sleep disorder characterized by the absence of muscle paralysis that normally occurs during the REM phase of sleep. This absence allows individuals to physically act out their dreams, which are often vivid and disturbing. Common behaviors exhibited during episodes include kicking, punching, and yelling. These actions can be dangerous, potentially leading to injuries for the person with RBD or their bed partner.
RBD is significantly associated with...
RBD is significantly associated with...
158
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
149
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
149
01:07Narcolepsy
92
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
92
01:14CNS Depressants: Barbiturates and Benzodiazepines
230
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
230